Back to results
US 12,427,152 B2Granted
HDAC inhibitors for use with NK cell based therapies
AssigneesViracta Therapeutics, Inc., NantKwest, Inc.
InventorsJames N. Woody, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.
Claims7
A method for treating an androgen-independent prostate cancer in an individual afflicted with the androgen-independent prostate cancer, the method comprising administering to the individual afflicted with the androgen-independent prostate cancer:
- a) CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide);
- and
- b) a primary human NK cell.
Dependencies are inferred from the claim text.